Contributed by: Dr. Nishtha Khatri & Dr. Tamhankar
Molnupiravir (EIDD-2801) is a new therapeutic and prophylactic drug being evaluated against COVID-19. It is a ribonucleoside analogue inhibitor of influenza virus and its mechanism of action is based on induction of error catastrophe in virus replication. The journal nature has published that in vivo research studies have shown that EIDD-2801 is efficacious in inhibiting SARS-CoV-2 replication. Currently, phase II/III clinical trials are being conducted to evaluate the safety and efficacy of EIDD-2801 in prevention and treatment of COVID-19. Since we still do not have a definitive treatment against COVID-19, immediate research initiatives as above are needed to explore the potential anti-viral treatments to combat SARS-CoV-2.
No comments:
Post a Comment